Perumal, Jai
Fox, Robert J.
Balabanov, Roumen
Balcer, Laura J.
Galetta, Steven
Makh, Shavy
Santra, Sourav
Hotermans, Christophe
Lee, Lily
Funding for this research was provided by:
Biogen (NA)
Article History
Received: 30 April 2018
Accepted: 20 May 2019
First Online: 8 June 2019
Ethics approval and consent to participate
: Prior to enrollment, all patients provided written informed consent, and approval was granted by an independent ethics committee for each study site (full list available in Additional file InternalRef removed).
: Not applicable.
: JP has received fees from Acorda, Biogen, Genzyme, and Teva. RJF has received consulting fees from Actelion, Biogen, Genentech, Mallinckrodt, MedDay, Novartis, Teva, and XenoPort, advisory board fees from Biogen and Novartis, and grant/research support from Novartis. RB has received consulting fees from Biogen, Sanofi, and Teva and grant/research support from Biogen. LB has received consulting fees from Biogen and Genzyme. SG has received consulting fees from Biogen. SM, CH, and LL are employees of and hold stock and/or stock options in Biogen. SS is an employee of Cytel.